MISSISSAUGA, ON, March 18 /PRNewswire-FirstCall/ - Vasogen Inc.
(NASDAQ:VSGN; TSX:VAS), a biotechnology Company focused on the research and
commercial development of technologies targeting the chronic inflammation
underlying cardiovascular and neurological disease, will provide a live
webcast presentation of its Annual and Special Meeting of Shareholders being
held at the MaRS Discovery District, Toronto, on Tuesday, March 25, 2008, at
4:30 p.m. ET.
To participate via webcast, please go to www.vasogen.com. A re-broadcast
of the webcast will also be available at www.vasogen.com.
About Vasogen:
Vasogen is a biotechnology company engaged in the research and commercial
development of therapies designed to target the destructive inflammatory
process associated with the development and progression of cardiovascular and
neurodegenerative disorders. The Company's lead product, the Celacade(TM)
System, is designed to activate the immune response to apoptosis - an
important physiological process that regulates inflammation. Celacade has
received European regulatory approval under the CE Mark for chronic heart
failure and is being marketed in the EU by Grupo Ferrer Internacional, S.A.
Celacade is also in late-stage clinical development for the treatment of
chronic heart failure in the United States. Vasogen is also developing a new
class of drugs for the treatment of certain neuro-inflammatory disorders.
VP025 is the lead candidate from this new class of drugs.
Certain statements contained in this press release, the upcoming
presentation and webcast, or elsewhere in our public documents constitute
"forward-looking statements" within the meaning of the United States Private
Securities Litigation Reform Act of 1995 and/or "forward-looking information"
under the Securities Act (Ontario). These statements may include, without
limitation, plans to advance the development of Celacade(TM) or VP025, plans
to fund our current activities, statements concerning our partnering
activities, health regulatory submissions, strategy, future operations, future
financial position, future revenues and projected costs. In some cases, you
can identify forward-looking statements by terminology such as "may", "will",
"should", "expects", "plans", "anticipates", "believes", "estimated",
"predicts", "potential", "continue", "intends", "could", or the negative of
such terms or other comparable terminology. We made a number of assumptions in
the preparation of these forward-looking statements, including assumptions
about the nature, size, and accessibility of the market for Celacade in the
treatment of chronic heart failure, particularly in Europe, the regulatory
approval process leading to commercialization and the availability of capital
on acceptable terms to pursue the development of Celacade, and the feasibility
of additional trials. You should not place undue reliance on our
forward-looking statements which are subject to a multitude of risks and
uncertainties that could cause actual results, future circumstances or events
to differ materially from those projected. These risks include, but are not
limited to, the outcome of further ongoing analysis of the ACCLAIM trial
results, the requirement or election to conduct additional clinical trials and
the size and design of any such trials, delays or setbacks in the regulatory
approval process, difficulties in the maintenance of existing regulatory
approvals, securing and maintaining corporate alliances, the need for
additional capital and the effect of capital market conditions and other
factors on capital availability, the potential dilutive effects of any
financing, risks associated with the outcomes of our preclinical and clinical
research and development programs, the adequacy, timing, and results of our
clinical trials, competition, market acceptance of our products, the
availability of government and insurance reimbursements for our products, the
strength of intellectual property, reliance on partners, subcontractors, and
key personnel, losses due to fluctuations in the U.S.-Canadian exchange rate,
and other risks detailed from time to time in our public disclosure documents
or other filings with the Canadian and U.S. securities commissions or other
securities regulatory bodies. Additional risks and uncertainties relating to
our Company and our business can be found in the "Risk Factors" section of our
Annual Information Form and Form 20-F for the year ended November 30, 2007, as
well as in our later public filings. The forward-looking statements are made
as of the date hereof, and we disclaim any intention and have no obligation or
responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.
SOURCE Vasogen Inc.